The Latest
-
Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses
-
Brokers name 3 ASX 200 shares to buy right now
-
How Moderna executives are cashing in on COVID-19 vaccine stock speculation
-
ASX 200 up 0.55%: Cochlear jumps on FDA approval, Adbri crushed on contract loss